{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:11:36Z","timestamp":1784013096081,"version":"3.55.0"},"publisher-location":"Cham","reference-count":95,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031849879","type":"print"},{"value":"9783031849886","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-84988-6_8","type":"book-chapter","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:56:01Z","timestamp":1749452161000},"page":"149-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute Lymphoid Leukemia: Is Transplant Indicated for Philadelphia Chromosome Positive ALL?"],"prefix":"10.1007","author":[{"given":"Ryszard","family":"Swoboda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","unstructured":"Advani AS, Moseley A, O'Dwyer KM, Wood BL, Park J, Wieduwilt M et al (2023) Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Adv 7(7):1279\u20131285. https:\/\/doi.org\/10.1182\/bloodadvances.2022008216","DOI":"10.1182\/bloodadvances.2022008216"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.bbmt.2015.03.021","volume":"21","author":"I Aldoss","year":"2015","unstructured":"Aldoss I, Stiller T, Cao TM, Palmer JM, Thomas SH, Forman SJ et al (2015) Impact of additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 21:1326\u20131329. https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.021","journal-title":"Biol Blood Marrow Transplant"},{"key":"8_CR3","doi-asserted-by":"publisher","unstructured":"Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G et al (2017) Safety and efficacy of Blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk 17(12):897\u2013901. https:\/\/doi.org\/10.1016\/j.clml.2017.08.101","DOI":"10.1016\/j.clml.2017.08.101"},{"key":"8_CR4","doi-asserted-by":"publisher","unstructured":"Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA et al (2020) Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv 4(10):2308\u20132316. https:\/\/doi.org\/10.1182\/bloodadvances.2019001381","DOI":"10.1182\/bloodadvances.2019001381"},{"key":"8_CR5","doi-asserted-by":"publisher","unstructured":"Bergfelt Lennmyr E, Engvall M, Barbany G, Fogelstrand L, Rhodin H, Hallb\u00f6\u00f6k H (2021) Cytogenetic aberrations in adult acute lymphoblastic leukemia-A population-based study. EJHaem 2(4):813\u2013817. https:\/\/doi.org\/10.1002\/jha2.300","DOI":"10.1002\/jha2.300"},{"key":"8_CR6","doi-asserted-by":"publisher","unstructured":"Burmeister T, Schwartz S, Bartram CR, G\u00f6kbuget N, Hoelzer D, Thiel E; GMALL study group (2008) Patients\u2019 age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood 112:918\u2013919. https:\/\/doi.org\/10.1182\/blood-2008-04-149286","DOI":"10.1182\/blood-2008-04-149286"},{"issue":"11","key":"8_CR7","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3390\/cancers16112108","volume":"16","author":"A Candoni","year":"2024","unstructured":"Candoni A, Chiusolo P, Lazzarotto D, Sartor C, Dargenio M, Chiaretti S et al (2024) Ponatinib as a prophylactic or pre-emptive strategy to prevent cytological relapse after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive Acute Lymphoblastic Leukemia transplanted in complete cytological remission. Cancers (Basel) 16(11):2108. https:\/\/doi.org\/10.3390\/cancers16112108","journal-title":"Cancers (Basel)"},{"issue":"24","key":"8_CR8","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F et al (2015) Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125(24):3711\u20133719. https:\/\/doi.org\/10.1182\/blood-2015-02-627935","journal-title":"Blood"},{"issue":"6","key":"8_CR9","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1002\/cam4.2153","volume":"8","author":"J Chang","year":"2019","unstructured":"Chang J, Douer D, Aldoss I, Vahdani G, Jeong AR, Ghaznavi Z et al (2019) Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia. Cancer Med 8(6):2832\u20132839. https:\/\/doi.org\/10.1002\/cam4.2153. Epub 2019 Apr 23","journal-title":"Cancer Med"},{"key":"8_CR10","doi-asserted-by":"publisher","unstructured":"Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XY et al (2012) Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. J Hematol Oncol 5:29. Published 2012 Jun 8. https:\/\/doi.org\/10.1186\/1756-8722-5-29","DOI":"10.1186\/1756-8722-5-29"},{"key":"8_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106930","volume":"121","author":"H Chen","year":"2022","unstructured":"Chen H, Xu LP, Zhang XH, Wang Y, Chen YH, Yan CH et al (2022) Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia patients with T315I mutation. Leuk Res 121:106930. https:\/\/doi.org\/10.1016\/j.leukres.2022.106930. Epub 2022 Aug 17","journal-title":"Leuk Res"},{"issue":"17","key":"8_CR12","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1182\/bloodadvances.2022009072","volume":"7","author":"LY Chen","year":"2023","unstructured":"Chen LY, Gong WJ, Li MH, Zhou HX, Xu MZ, Qian CS et al (2023) Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. Blood Adv 7(17):4913\u20134925. https:\/\/doi.org\/10.1182\/bloodadvances.2022009072","journal-title":"Blood Adv"},{"issue":"7","key":"8_CR13","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","volume":"106","author":"S Chiaretti","year":"2021","unstructured":"Chiaretti S, Ansuinelli M, Vitale A, Elia L, Matarazzo M, Piciocchi A et al (2021) A multicenter total therapy strategy for de novo adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. Haematologica 106(7):1828\u20131838. https:\/\/doi.org\/10.3324\/haematol.2020.260935","journal-title":"Haematologica"},{"issue":"3","key":"8_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/10428194.2020.1844198","volume":"62","author":"MA Couturier","year":"2021","unstructured":"Couturier MA, Thomas X, Raffoux E, Huguet F, Berthon C, Simand C et al (2021) Blinatumomab + ponatinib for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leuk Lymphoma 62(3):620\u2013629. https:\/\/doi.org\/10.1080\/10428194.2020.1844198. Epub 2020 Nov 6","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"8_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3324\/haematol.2014.118588","volume":"100","author":"N Daver","year":"2015","unstructured":"Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E et al (2015) Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 100(5):653\u2013661. https:\/\/doi.org\/10.3324\/haematol.2014.118588","journal-title":"Haematologica"},{"key":"8_CR16","doi-asserted-by":"crossref","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) (2007) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109(4):1408\u20131413","DOI":"10.1182\/blood-2006-03-011908"},{"issue":"15","key":"8_CR17","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","volume":"1","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA et al (2017) Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv 1(15):1167\u20131180. https:\/\/doi.org\/10.1182\/bloodadvances.2016001925","journal-title":"Blood Adv"},{"key":"8_CR18","doi-asserted-by":"publisher","unstructured":"Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X et al; de Traitement de la Leuc\u00e9mie Aigu\u00eb Lymphoblastique de l'Adulte (GET-LALA Group) (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2013results of the prospective multicenter LALA-94 trial. Blood 100(7):2357\u20132366. https:\/\/doi.org\/10.1182\/blood-2002-03-0704","DOI":"10.1182\/blood-2002-03-0704"},{"issue":"5","key":"8_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561\u2013566","journal-title":"Nat Med"},{"issue":"11","key":"8_CR20","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","volume":"91","author":"S Faderl","year":"1998","unstructured":"Faderl S, Kantarjian HM, Talpaz M, Estrov Z (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91(11):3995\u20134019","journal-title":"Blood"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ et al (2009) Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms the superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993. Blood 113:4489\u20134496. https:\/\/doi.org\/10.1182\/blood-2009-01-199380","journal-title":"Blood"},{"issue":"6","key":"8_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","volume":"123","author":"AK Fielding","year":"2014","unstructured":"Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR et al (2014) UKALLXII\/ECOG2993: the addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia-positive acute lymphoblastic leukemia. Blood 123(6):843\u2013850. https:\/\/doi.org\/10.1182\/blood-2013-09-529008. Epub 2013 Nov 25","journal-title":"Blood"},{"key":"8_CR23","doi-asserted-by":"publisher","unstructured":"Fo\u00e0 R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS et al; GIMEMA Acute Leukemia Working Party (2011) Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 118(25):6521\u20136528. https:\/\/doi.org\/10.1182\/blood-2011-05-351403. Epub 2011 Sep 19","DOI":"10.1182\/blood-2011-05-351403"},{"key":"8_CR24","doi-asserted-by":"publisher","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC et al; GIMEMA investigators (2020) Dasatinib-Blinatumomab for Ph-positive Acute Lymphoblastic Leukemia in adults. N Engl J Med 383(17):1613\u20131623. https:\/\/doi.org\/10.1056\/NEJMoa2016272","DOI":"10.1056\/NEJMoa2016272"},{"issue":"8","key":"8_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M et al (2024) Long-term results of the Dasatinib-Blinatumomab Protocol for adult Philadelphia-positive ALL. J Clin Oncol 42(8):881\u2013885. https:\/\/doi.org\/10.1200\/JCO.23.01075. Epub 2023 Dec 21","journal-title":"J Clin Oncol"},{"issue":"4","key":"8_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajh.24653","volume":"92","author":"S Fujisawa","year":"2017","unstructured":"Fujisawa S, Mizuta S, Akiyama H, Ueda Y, Aoyama Y, Hatta Y et al (2017) Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Am J Hematol 92(4):367\u2013374. https:\/\/doi.org\/10.1002\/ajh.24653. Epub 2017 Feb 21","journal-title":"Am J Hematol"},{"issue":"20","key":"8_CR27","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA et al (2022) The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood 140(20):2101\u20132112. https:\/\/doi.org\/10.1182\/blood.2022016194","journal-title":"Blood"},{"issue":"19","key":"8_CR28","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"S Giebel","year":"2016","unstructured":"Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F et al (2016) Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and marrow transplantation. Cancer 122(19):2941\u20132951. https:\/\/doi.org\/10.1002\/cncr.30130. Epub 2016 Jun 16","journal-title":"Cancer"},{"issue":"24","key":"8_CR29","doi-asserted-by":"publisher","first-page":"00547","DOI":"10.1016\/j.jtct.2024.07.016","volume":"S2666\u20136367","author":"S Giebel","year":"2024","unstructured":"Giebel S, Labopin M, Peric Z, Passweg J, Blaise D, Salmenniemi U et al (2024) Impact of the type of tyrosine kinase inhibitor (imatinib or dasatinib) used before allo-HCT on outcome of patients with Philadelphia-positive acute lymphoblastic leukemia. A study on behalf of the Acute Leukemia Working Party of the EBMT. Transplant Cell Ther S2666\u20136367(24):00547\u201300545. https:\/\/doi.org\/10.1016\/j.jtct.2024.07.016","journal-title":"Transplant Cell Ther"},{"key":"8_CR30","doi-asserted-by":"publisher","unstructured":"Guan F, Yang L, Chen Y, Shi J, Song X, Lai X et al (2024) Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: a multicenter retrospective study. Cancer 130(12):2139\u20132149. https:\/\/doi.org\/10.1002\/cncr.35232","DOI":"10.1002\/cncr.35232"},{"issue":"8","key":"8_CR31","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1080\/10428194.2017.1411595","volume":"59","author":"A Hanif","year":"2018","unstructured":"Hanif A, Wang ES, Thompson JE, Baron JI, Walsh MD, Griffiths EA (2018) Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed\/refractory acute lymphoblastic leukemia. Leuk Lymphoma 59(8):2011\u20132013. https:\/\/doi.org\/10.1080\/10428194.2017.1411595","journal-title":"Leuk Lymphoma"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1007\/s00277-024-05682-3","volume":"103","author":"L Hu","year":"2024","unstructured":"Hu L, Li Z, Yang S, Zhao T, Duan W, Qin Y et al (2024) Allogeneic stem cell transplantation is still a highly curative therapy in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Ann Hematol 103:3745. https:\/\/doi.org\/10.1007\/s00277-024-05682-3","journal-title":"Ann Hematol"},{"issue":"12","key":"8_CR33","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","volume":"5","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD et al (2018a) Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-center, phase 2 study. Lancet Haematol 5(12):e618\u2013e627. https:\/\/doi.org\/10.1016\/S2352-3026(18)30176-5","journal-title":"Lancet Haematol"},{"issue":"4","key":"8_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.clml.2018.02.010","volume":"18","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ et al (2018b) Efficacy of Ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18(4):257\u2013265. https:\/\/doi.org\/10.1016\/j.clml.2018.02.010. Epub 2018 Feb 17","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"8_CR35","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P et al (2023) Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24\u2013e34. https:\/\/doi.org\/10.1016\/S2352-3026(22)00319-2. Epub 2022 Nov 16","journal-title":"Lancet Haematol"},{"issue":"21","key":"8_CR36","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D et al (2024a) Ponatinib vs Imatinib in frontline Philadelphia chromosome-positive Acute Lymphoblastic Leukemia: a randomized clinical trial. JAMA 331(21):1814\u20131823. https:\/\/doi.org\/10.1001\/jama.2024.4783","journal-title":"JAMA"},{"key":"8_CR37","doi-asserted-by":"publisher","unstructured":"Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K et al (2024b) Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417\u2013421. https:\/\/doi.org\/10.1182\/blood.2023022330","DOI":"10.1182\/blood.2023022330"},{"issue":"8","key":"8_CR38","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ajh.26238","volume":"96","author":"N Jain","year":"2021","unstructured":"Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T et al (2021) Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol 96(8):1000\u20131007. https:\/\/doi.org\/10.1002\/ajh.26238. Epub 2021 May 28","journal-title":"Am J Hematol"},{"issue":"8","key":"8_CR39","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W et al (2016) Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic Leukemia. N Engl J Med 375(8):740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277. Epub 2016 Jun 12","journal-title":"N Engl J Med"},{"issue":"14","key":"8_CR40","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G\u00f6kbuget N et al (2019) Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer 125(14):2474\u20132487. https:\/\/doi.org\/10.1002\/cncr.32116. Epub 2019 Mar 28","journal-title":"Cancer"},{"key":"8_CR41","doi-asserted-by":"publisher","unstructured":"Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG et al (2023) Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493\u2013501. https:\/\/doi.org\/10.1002\/ajh.26816","DOI":"10.1002\/ajh.26816"},{"key":"8_CR42","doi-asserted-by":"publisher","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G et al (2024) Results of the simultaneous combination of Ponatinib and Blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol 42:4246-4251 https:\/\/doi.org\/10.1200\/JCO.24.00272","DOI":"10.1200\/JCO.24.00272"},{"key":"8_CR43","doi-asserted-by":"publisher","unstructured":"Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH et al (2015) Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood 126(6):746\u2013756. https:\/\/doi.org\/10.1182\/blood-2015-03-636548","DOI":"10.1182\/blood-2015-03-636548"},{"issue":"9","key":"8_CR44","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","volume":"19","author":"KH Lee","year":"2005","unstructured":"Lee KH, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS et al (2005) Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19(9):1509\u20131516. https:\/\/doi.org\/10.1038\/sj.leu.2403886","journal-title":"Leukemia"},{"issue":"7","key":"8_CR45","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00277-021-04504-0","volume":"100","author":"S Leotta","year":"2021","unstructured":"Leotta S, Markovic U, Pirosa MC, Stella S, Tringali S, Martino M et al (2021) The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. Ann Hematol 100(7):1743\u20131753. https:\/\/doi.org\/10.1007\/s00277-021-04504-0. Epub 2021 Mar 28","journal-title":"Ann Hematol"},{"key":"8_CR46","doi-asserted-by":"publisher","unstructured":"Liu H, Xuan L, Lin R, Deng L, Fan Z, Nie D et al (2021) A new pre-emptive TKIs strategy for preventing relapse based on BCR\/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study. Leukemia 35(7):2054\u20132063. https:\/\/doi.org\/10.1038\/s41375-020-01090-4","DOI":"10.1038\/s41375-020-01090-4"},{"issue":"29","key":"8_CR47","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038985","volume":"103","author":"T Liu","year":"2024","unstructured":"Liu T, Wang C, Fu Y, Yang YP, Tan YH (2024) Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report. Medicine (Baltimore) 103(29):e38985. https:\/\/doi.org\/10.1097\/MD.0000000000038985","journal-title":"Medicine (Baltimore)"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.beha.2022.101414","volume":"35","author":"A Marinos","year":"2022","unstructured":"Marinos A, Heslop HE (2022) Should all CAR-T therapy for acute lymphoblastic leukemia be consolidated with an allogeneic stem cell transplant? Best Pract Res Clin Hematol 35:101414","journal-title":"Best Pract Res Clin Hematol"},{"key":"8_CR49","doi-asserted-by":"crossref","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Topp MS et al (2017) Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with Blinatumomab: results from a Phase II, single-arm, multicenter study. J Clin Oncol. 2017 Jun 1;35(16):1795-1802. doi: 10.1200\/JCO.2016.69.3531. Epub 2017 Mar 29. Erratum in: J Clin Oncol. 2017 Aug 10;35(23):2722. doi: 10.1200\/JCO.2017.74.7550. Erratum in: J Clin Oncol. 2017 Aug 20;35(24):2856. doi: 10.1200\/JCO.2017.75.0489","DOI":"10.1200\/JCO.2017.75.0489"},{"key":"8_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","volume":"146","author":"G Martinelli","year":"2021","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Rambaldi A et al (2021) Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. Eur J Cancer 146:107\u2013114. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.022. Epub 2021 Feb 13","journal-title":"Eur J Cancer"},{"issue":"6","key":"8_CR51","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","volume":"6","author":"G Martinelli","year":"2022","unstructured":"Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C et al (2022) INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv 6(6):1742\u20131753. https:\/\/doi.org\/10.1182\/bloodadvances.2021004821","journal-title":"Blood Adv"},{"key":"8_CR52","doi-asserted-by":"publisher","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","DOI":"10.1056\/NEJMoa1709866"},{"key":"8_CR53","doi-asserted-by":"publisher","first-page":"1717506","DOI":"10.1155\/2021\/1717506","volume":"2021","author":"I Micheva","year":"2021","unstructured":"Micheva I, Gerov V, Dimitrova S, Efraim M (2021) Efficacy of Inotuzumab Ozogamicin plus Ponatinib followed by allogeneic stem cell transplantation in a patient with relapsed Philadelphia chromosome-positive Acute Lymphoblastic Leukemia. Case Rep Hematol 2021:1717506. Published 2021 May 26. https:\/\/doi.org\/10.1155\/2021\/1717506","journal-title":"Case Rep Hematol"},{"key":"8_CR54","doi-asserted-by":"publisher","unstructured":"Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H et al (2017) Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130(18):2027\u20132031. https:\/\/doi.org\/10.1182\/blood-2017-05-782888","DOI":"10.1182\/blood-2017-05-782888"},{"issue":"12","key":"8_CR55","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.clml.2020.07.005","volume":"20","author":"S Nanno","year":"2020","unstructured":"Nanno S, Matsumoto K, Nakamae M, Okamura H, Nishimoto M, Hirose A et al (2020) Effect of prophylactic post-transplant ponatinib administration on outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 20(12):813\u2013819.e1. https:\/\/doi.org\/10.1016\/j.clml.2020.07.005. Epub 2020 Jul 16","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"8_CR56","doi-asserted-by":"publisher","unstructured":"Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N et al; Japan Adult Leukemia Study Group (2024) Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. Am J Hematol 99(5):806\u2013815. https:\/\/doi.org\/10.1002\/ajh.27237. Epub 2024 Feb 5","DOI":"10.1002\/ajh.27237"},{"key":"8_CR57","doi-asserted-by":"publisher","unstructured":"O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401\u2013412. https:\/\/doi.org\/10.1016\/j.ccr.2009.09.028","DOI":"10.1016\/j.ccr.2009.09.028"},{"issue":"21","key":"8_CR58","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood.V124.21.798.798","volume":"124","author":"G Oliver","year":"2014","unstructured":"Oliver G, Ottmann HP, Cayuela J-M, Spiekermann K, Beck J, Jung WE et al (2014) Nilotinib (Tasigna\u00ae) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome\/BCR-ABL1 positive Acute Lymphoblastic Leukemia (ALL): a trial of the European Working Group for Adult ALL (EWALL-PH-02). Blood 124(21):798. https:\/\/doi.org\/10.1182\/blood.V124.21.798.798","journal-title":"Blood"},{"issue":"7","key":"8_CR59","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","volume":"110","author":"O Ottmann","year":"2007","unstructured":"Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA et al (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110(7):2309\u20132315. https:\/\/doi.org\/10.1182\/blood-2007-02-073528. Epub 2007 May 11","journal-title":"Blood"},{"key":"8_CR60","doi-asserted-by":"publisher","unstructured":"Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornh\u00e4user M, Stadler M et al (2013) Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia 27(6):1254\u20131262. https:\/\/doi.org\/10.1038\/leu.2012.352","DOI":"10.1038\/leu.2012.352"},{"issue":"13","key":"8_CR61","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood-2017-07-796862","volume":"131","author":"H Pfeifer","year":"2018","unstructured":"Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Obl\u00e4nder J et al (2018) Genomic CDKN2A\/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood 131(13):1464\u20131475. https:\/\/doi.org\/10.1182\/blood-2017-07-796862. Epub 2018 Jan 18","journal-title":"Blood"},{"issue":"Suppl 1","key":"8_CR62","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/10428194.2010.546922","volume":"52","author":"LC Platanias","year":"2011","unstructured":"Platanias LC (2011) Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 52(Suppl 1):2\u20133. https:\/\/doi.org\/10.3109\/10428194.2010.546922","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"8_CR63","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","volume":"3","author":"MA Pulsipher","year":"2022","unstructured":"Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S et al (2022) Next-generation sequencing of minimal residual disease for predicting relapse after Tisagenlecleucel in children and young adults with Acute Lymphoblastic Leukemia. Blood Cancer Discov 3(1):66\u201381. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0095","journal-title":"Blood Cancer Discov"},{"issue":"23","key":"8_CR64","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.29646","volume":"121","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S et al (2015) Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(23):4158\u20134164. https:\/\/doi.org\/10.1002\/cncr.29646. Epub 2015 Aug 26","journal-title":"Cancer"},{"issue":"3","key":"8_CR65","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","volume":"1","author":"F Ravandi","year":"2016","unstructured":"Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC et al (2016) US Intergroup Study of Chemotherapy Plus Dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Adv 1(3):250\u2013259. https:\/\/doi.org\/10.1182\/bloodadvances.2016001495","journal-title":"Blood Adv"},{"issue":"1","key":"8_CR66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2141.2012.09240.X","volume":"159","author":"JM Ribera","year":"2012","unstructured":"Ribera JM, Garc\u00eda O, Montesinos P, Brunet S, Abella E, Barrios M et al (2012) Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol 159(1):78\u201381. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09240.X. Epub 2012 Jul 24","journal-title":"Br J Haematol"},{"issue":"18","key":"8_CR67","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1182\/bloodadvances.2022007764","volume":"6","author":"JM Ribera","year":"2022","unstructured":"Ribera JM, Garc\u00eda-Calduch O, Ribera J, Montesinos P, Cano-Ferri I, Mart\u00ednez P et al (2022) Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv 6(18):5395\u20135402. https:\/\/doi.org\/10.1182\/bloodadvances.2022007764","journal-title":"Blood Adv"},{"issue":"7","key":"8_CR68","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1007\/s12325-023-02497-y","volume":"40","author":"JM Ribera","year":"2023","unstructured":"Ribera JM, Prawitz T, Freitag A, Sharma A, Dobi B, Rizzo F et al (2023) Ponatinib vs. Imatinib as frontline treatment for Philadelphia chromosome-positive Acute Lymphoblastic Leukemia: a matching adjusted indirect comparison. Adv Ther 40(7):3087\u20133103. https:\/\/doi.org\/10.1007\/s12325-023-02497-y. Epub 2023 May 19","journal-title":"Adv Ther"},{"key":"8_CR69","doi-asserted-by":"publisher","unstructured":"Ribera JM, Morgades M, Ribera J, Montesinos P, Cano-Ferri I, Mart\u00ednez P et al (2024) Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: long-term results. Hema 8(4):e67. Published 2024 Apr 2. https:\/\/doi.org\/10.1002\/hem3.67","DOI":"10.1002\/hem3.67"},{"issue":"2","key":"8_CR70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","volume":"22","author":"KG Roberts","year":"2012","unstructured":"Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al (2012) Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22(2):153\u2013166. https:\/\/doi.org\/10.1016\/j.ccr.2012.06.005","journal-title":"Cancer Cell"},{"key":"8_CR71","doi-asserted-by":"publisher","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM et al; European Working Group on Adult ALL (EWALL) group (2016) Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 128(6):774\u2013782. https:\/\/doi.org\/10.1182\/blood-2016-02-700153. Epub 2016 Apr 27","DOI":"10.1182\/blood-2016-02-700153"},{"issue":"23","key":"8_CR72","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1002\/cncr.30231","volume":"122","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G et al (2016) Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer 122(23):3650\u20133656. https:\/\/doi.org\/10.1002\/cncr.30231. Epub 2016 Aug 1","journal-title":"Cancer"},{"issue":"15","key":"8_CR73","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/cncr.33529","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R et al (2021) Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648\u20132656. https:\/\/doi.org\/10.1002\/cncr.33529. Epub 2021 Apr 1","journal-title":"Cancer"},{"key":"8_CR74","doi-asserted-by":"publisher","unstructured":"Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H et al (2022) Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia 36(5):1253\u20131260. https:\/\/doi.org\/10.1038\/s41375-021-01496-8. Epub 2022 Feb 7. Erratum in: Leukemia. 2022 May; 36(5):1448. https:\/\/doi.org\/10.1038\/s41375-022-01568-3","DOI":"10.1038\/s41375-021-01496-8"},{"issue":"5682","key":"8_CR75","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, NY) 305(5682):399\u2013401. https:\/\/doi.org\/10.1126\/science.1099480","journal-title":"Science (New York, NY)"},{"key":"8_CR76","doi-asserted-by":"publisher","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD et al (2021) KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398(10299):491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8","DOI":"10.1016\/S0140-6736(21)01222-8"},{"issue":"3","key":"8_CR77","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.clml.2023.01.002","volume":"23","author":"M Shahzad","year":"2023","unstructured":"Shahzad M, Hussain A, Tariq E, Anwar I, Faisal MS, Syed L et al (2023) Outcomes of tyrosine kinase inhibitors maintenance therapy with or without allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome positive Acute Lymphoblastic Leukemia in first complete remission: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 23(3):178\u2013187. https:\/\/doi.org\/10.1016\/j.clml.2023.01.002. Epub 2023 Jan 12","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"8_CR78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-022-00265-2","volume":"11","author":"T Shi","year":"2022","unstructured":"Shi T, Xie M, Chen L, Yuan W, Wang Y, Huang X et al (2022) Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era. Exp Hematol Oncol 11(1):13. https:\/\/doi.org\/10.1186\/s40164-022-00265-2","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"8_CR79","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE et al (2016) Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504\u2013507. https:\/\/doi.org\/10.1182\/blood-2016-03-707562. Epub 2016 May 27","journal-title":"Blood"},{"issue":"3","key":"8_CR80","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajh.24625","volume":"92","author":"NJ Short","year":"2017","unstructured":"Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C et al (2017) Poor outcomes associated with +der (22)t(9;22) and \u22129\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238\u2013243. https:\/\/doi.org\/10.1002\/ajh.24625. Epub 2017 Feb 3","journal-title":"Am J Hematol"},{"issue":"22","key":"8_CR81","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","volume":"36","author":"WB Slayton","year":"2018","unstructured":"Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA et al (2018) Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children's oncology group trial AALL0622. J Clin Oncol 36(22):2306\u20132314. https:\/\/doi.org\/10.1200\/JCO.2017.76.7228. Epub 2018 May 29","journal-title":"J Clin Oncol"},{"issue":"6","key":"8_CR82","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cncr.33321","volume":"127","author":"W Stock","year":"2021","unstructured":"Stock W, Martinelli G, Stelljes M, DeAngelo DJ, G\u00f6kbuget N, Advani AS et al (2021) Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia. Cancer 127(6):905\u2013913. https:\/\/doi.org\/10.1002\/cncr.33321. Epub 2020 Nov 24","journal-title":"Cancer"},{"issue":"2","key":"8_CR83","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/bloodadvances.2021004607","volume":"6","author":"I Sugiura","year":"2022","unstructured":"Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y et al (2022) Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv 6(2):624\u2013636. https:\/\/doi.org\/10.1182\/bloodadvances.2021004607","journal-title":"Blood Adv"},{"issue":"12","key":"8_CR84","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM et al (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396\u20134407","journal-title":"Blood"},{"issue":"11","key":"8_CR86","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.Can-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE et al (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66(11):5790\u20135797. https:\/\/doi.org\/10.1158\/0008-5472.Can-05-4187","journal-title":"Cancer Res"},{"key":"8_CR87","doi-asserted-by":"crossref","unstructured":"Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M et al; Japan Adult Leukemia Study Group (2004) Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104(12):3507\u20133512","DOI":"10.1182\/blood-2004-04-1389"},{"key":"8_CR88","doi-asserted-by":"crossref","unstructured":"Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M et al (2006) Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 108(5):1469\u20131477","DOI":"10.1182\/blood-2005-11-4386"},{"issue":"3","key":"8_CR89","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1046\/j.1365-2141.2003.04736.x","volume":"124","author":"M Wetzler","year":"2004","unstructured":"Wetzler M, Dodge RK, Mr\u00f3zek K, Stewart CC, Carroll AJ, Tantravahi R et al (2004) Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the cancer and Leukaemia group B. Br J Haematol 124(3):275\u2013288. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04736.x","journal-title":"Br J Haematol"},{"key":"8_CR90","doi-asserted-by":"publisher","unstructured":"Xie M, Lu Y, Ouyang G, Li X, Shi T, Yang M et al (2023a) Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: a single-arm, multicentre, phase 2 trial. Br J Haematol 202(6):1119\u20131126. https:\/\/doi.org\/10.1111\/bjh.18975","DOI":"10.1111\/bjh.18975"},{"issue":"10","key":"8_CR91","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/cncr.34710","volume":"129","author":"M Xie","year":"2023","unstructured":"Xie M, Shi T, Jiang Q, Jia Y, Zhou D, Tong H et al (2023b) Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 129(10):1523\u20131536. https:\/\/doi.org\/10.1002\/cncr.34710. Epub 2023 Mar 7","journal-title":"Cancer"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-016-0270-5","volume":"9","author":"N Xu","year":"2016","unstructured":"Xu N, Li YL, Li X, Zhou X, Cao R, Li H et al (2016) Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol 9:40. https:\/\/doi.org\/10.1186\/s13045-016-0270-5","journal-title":"J Hematol Oncol"},{"key":"8_CR93","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.2147\/DDDT.S150317","volume":"12","author":"IR Yurkiewicz","year":"2018","unstructured":"Yurkiewicz IR, Muffly L, Liedtke M (2018) Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Drug Des Devel Ther 12:2293\u20132300. https:\/\/doi.org\/10.2147\/DDDT.S150317","journal-title":"Drug Des Devel Ther"},{"issue":"24","key":"8_CR94","doi-asserted-by":"publisher","first-page":"8741","DOI":"10.1002\/cam4.4413","volume":"10","author":"Q Zeng","year":"2021","unstructured":"Zeng Q, Xiang B, Liu Z (2021) Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Med 10(24):8741\u20138753. https:\/\/doi.org\/10.1002\/cam4.4413. Epub 2021 Nov 11","journal-title":"Cancer Med"},{"issue":"8","key":"8_CR95","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1007\/s00277-024-05871-0","volume":"103","author":"J Zheng","year":"2024","unstructured":"Zheng J, Zhao Y, Luo Y, Yu J, Lai X, Wang J et al (2024) Impact of additional cytogenetic aberrations at diagnosis on prognosis of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: a retrospective analysis. Ann Hematol 103(8):2983\u20132991. https:\/\/doi.org\/10.1007\/s00277-024-05871-0. Epub 2024 Jul 4","journal-title":"Ann Hematol"},{"issue":"1","key":"8_CR96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/intimm\/dxu089","volume":"27","author":"Z Zimmerman","year":"2015","unstructured":"Zimmerman Z, Maniar T, Nagorsen D (2015) Unleashing the clinical power of T cells: CD19\/CD3 bi-specific T cell engager (BiTE\u00ae) antibody construct blinatumomab as a potential therapy. Int Immunol 27(1):31\u201337. https:\/\/doi.org\/10.1093\/intimm\/dxu089","journal-title":"Int Immunol"}],"container-title":["Advances in Experimental Medicine and Biology","Clinical Management of Challenges in Allogeneic Stem Cell Transplant"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-84988-6_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:56:05Z","timestamp":1749452165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-84988-6_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031849879","9783031849886"],"references-count":95,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-84988-6_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"10 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}